<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01979276</url>
  </required_header>
  <id_info>
    <org_study_id>1306014005</org_study_id>
    <nct_id>NCT01979276</nct_id>
  </id_info>
  <brief_title>Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma</brief_title>
  <acronym>Romi Poma</acronym>
  <official_title>A Phase I/II Study of Pomalidomide (CC-4047®), Dexamethasone and Romidepsin in Patients With Relapsed or Refractory Multiple Myeloma (Romi Poma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <brief_summary>
    <textblock>
      This clinical trial is for subjects with multiple myeloma that has returned after treatment&#xD;
      (relapsed) or did not respond to prior treatment (refractory). The study is in two parts,&#xD;
      Phase I and Phase II. Phase I will determine the maximum tolerated dose of romidepsin in&#xD;
      combination with pomalidomide and dexamethasone. The purpose of Phase II is to evaluate the&#xD;
      effectiveness of combining romidepsin with pomalidomide and dexamethasone. The hypothesis is&#xD;
      that overall response in a cohort of patients treated with romidepsin + pomalidomide +&#xD;
      dexamethasone will be 60 percent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I/II study is a treatment program for patients with relapsed or refractory&#xD;
      multiple myeloma. Up to 48 patients will be enrolled. Phase I will follow a 3+3 dose&#xD;
      escalation design to find the maximum tolerated dose of romidepsin in combination with&#xD;
      pomalidomide and dexamethasone.&#xD;
&#xD;
      In Phase I, subjects will receive:&#xD;
&#xD;
        -  Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle&#xD;
&#xD;
        -  Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle&#xD;
&#xD;
        -  Romidepsin intravenously (9 mg/m2, 12 mg/m2, 15 mg/m2 or 18 mg/m2) on days 1 and 15 of a&#xD;
           28-day cycle.&#xD;
&#xD;
      Phase II will expand the number of subjects in the MTD arm of the trial until 48 subjects are&#xD;
      enrolled. In Phase II, subjects subjects will receive:&#xD;
&#xD;
        -  Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle&#xD;
&#xD;
        -  Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle&#xD;
&#xD;
        -  Romidepsin intravenously on days 1 and 15 of a 28-day cycle at the Maximum Tolerated&#xD;
           Dose determined by Phase I&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    this study was terminated due to losing financial support, and enrollment challenges&#xD;
  </why_stopped>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Romidepsin in Combination With Pomalidomide and Dexamethasone</measure>
    <time_frame>During the duration of the study (from first to last dose of study drug, on average ten 28-day cycles)</time_frame>
    <description>Establish a maximum tolerated dose (MTD) of romidepsin in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (phase I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Study Regimen Combination</measure>
    <time_frame>From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days</time_frame>
    <description>The efficacy (as assessed by clinical response) of the combination of pomalidomide (CC-4047®) and romidepsin as therapy for patients with relapsed or refractory multiple myeloma (MM) (phase II portion) was evaluated using the IMWG Response Criteria for disease assessment. The best response was reported. (Criteria can be found at the following link, due to length and complexity of the response criteria: http://imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression (Progression Free Survival)</measure>
    <time_frame>From start of treatment, to date of disease progression (on average, ten 28-day cycles)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide, Romidepsin, Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Romidepsin intravenously on days 1 and 15 of a 28-day cycle</description>
    <arm_group_label>Pomalidomide, Romidepsin, Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pomalidomide</intervention_name>
    <description>Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle</description>
    <arm_group_label>Pomalidomide, Romidepsin, Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle</description>
    <arm_group_label>Pomalidomide, Romidepsin, Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed multiple myeloma.&#xD;
&#xD;
          -  measurable disease as defined by &gt; 0.5 g/dL serum monoclonal protein, &gt;0.1 g/dL serum&#xD;
             free light chains, &gt;0.2 g/24 hrs urinary M-protein excretion, and/or measurable&#xD;
             plasmacytoma(s).&#xD;
&#xD;
          -  relapsed or refractory multiple myeloma as defined by progression of disease either&#xD;
             after prior therapy or lack of response to currently used therapy&#xD;
&#xD;
          -  relapsed or progressive disease after at least 3 prior therapeutic treatments or&#xD;
             regimens for multiple myeloma.&#xD;
&#xD;
          -  refractory to bortezomib and lenalidomide&#xD;
&#xD;
          -  &gt;18 years at the time of signing the informed consent form.&#xD;
&#xD;
          -  life expectancy of &gt; 3 months.&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70%, or &gt; 60% if due to bony involvement of multiple&#xD;
             myeloma&#xD;
&#xD;
          -  normal organ and marrow function as defined below:&#xD;
&#xD;
               1. Absolute Neutrophil Count &gt; 1,000 cells/mm3 for Phase I, &gt; 750 cells/mm3 for&#xD;
                  Phase II&#xD;
&#xD;
               2. Platelet Count &gt; 75,000/mm3 for Phase I, &gt; 50, 000/mm3 for Phase II&#xD;
&#xD;
               3. AST/ Serum SGOT &lt; 3.0 x upper limits of normal&#xD;
&#xD;
               4. ALT/ Serum SGPT &lt; 3.0 x upper limit of normal&#xD;
&#xD;
               5. Serum creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
               6. Serum total bilirubin &lt; 1.5 x upper limit of normal&#xD;
&#xD;
          -  Laboratory test results within these ranges:&#xD;
&#xD;
             g. Serum potassium ≥ 3.8 mmol/L h. Serum magnesium &gt;1.8 mg/dL&#xD;
&#xD;
          -  Females of child bearing potential (FCBP) must have a negative serum or urine&#xD;
             pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to&#xD;
             start of study drug(s) and again with 24 hours of prescribing pomalidomide&#xD;
             (prescriptions must be filled within 7 days).&#xD;
&#xD;
          -  Females of child bearing potential must either commit to continued abstinence from&#xD;
             heterosexual intercourse or begin TWO acceptable methods of birth control, one highly&#xD;
             effective method and one additional effective method AT THE SAME TIME, at least 4&#xD;
             weeks before starting pomalidomide. FCBP must also agree to ongoing pregnancy testing.&#xD;
             Men must agree to use a latex condom during sexual contact with females of child&#xD;
             bearing potential even if they have had a successful vasectomy.&#xD;
&#xD;
          -  able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients&#xD;
             intolerant to ASA may use warfarin or low molecular weight heparin).&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with non-secretory Multiple Myeloma (no measurable monoclonal protein or&#xD;
             plasmacytoma(s), free light chains, and/or M-spike in blood or urine).&#xD;
&#xD;
          -  Patients with a prior history of other malignancies (except for basal cell or squamous&#xD;
             cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless&#xD;
             disease free for ≥ 3 years.&#xD;
&#xD;
          -  Any known cardiac abnormalities such as:&#xD;
&#xD;
               1. Congenital long QT syndrome&#xD;
&#xD;
               2. QTc interval ≥ 480 milliseconds&#xD;
&#xD;
               3. Myocardial infarction within 6 months of C1D1. Subjects with a history of&#xD;
                  myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic&#xD;
                  and have had a negative cardiac risk assessment (treadmill stress test, nuclear&#xD;
                  medicine stress test, or stress echocardiogram) since the event may participate&#xD;
&#xD;
               4. Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV)&#xD;
                  block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50&#xD;
                  beats/min)&#xD;
&#xD;
               5. Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV. In&#xD;
                  any subject in whom there is doubt, the subject should have a stress imaging&#xD;
                  study and, if abnormal, angiography to define whether or not CAD is present&#xD;
&#xD;
               6. An ECG recorded at screening showing evidence of cardiac ischemia (ST depression&#xD;
                  depression of ≥2 mm, measured from isoelectric line to the ST segment). If in any&#xD;
                  doubt, the patient should have a stress imaging study and, if abnormal,&#xD;
                  angiography to define whether or not CAD is present&#xD;
&#xD;
               7. Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class&#xD;
                  II to IV definitions (see Appendix E) and/or ejection fraction &lt;40% by MUGA scan&#xD;
                  or &lt;50% by echocardiogram and/or MRI;&#xD;
&#xD;
               8. A known history of sustained ventricular tachycardia (VT), ventricular&#xD;
                  fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently&#xD;
                  addressed with an automatic implantable cardioverter defibrillator (AICD);&#xD;
&#xD;
               9. Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or&#xD;
                  other causes;&#xD;
&#xD;
              10. Uncontrolled hypertension, i.e., blood pressure (BP) of ≥160/95; patients who&#xD;
                  have a history of hypertension controlled by medication must be on a stable dose&#xD;
                  (for at least one month) and meet all other inclusion criteria; or&#xD;
&#xD;
              11. Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable&#xD;
                  doses of beta-blockers)&#xD;
&#xD;
          -  Any Known seropositivity for or active viral infection with human immunodeficiency&#xD;
             virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are&#xD;
             seropositive because of hepatitis B virus vaccine are eligible.&#xD;
&#xD;
          -  Any active viral or bacterial infections or any coexisting medical problem that would&#xD;
             significantly increase the risks of this treatment program.&#xD;
&#xD;
          -  Any coexisting medical problem or laboratory evaluation that, in the treating&#xD;
             physician's or principal investigator's opinion, makes the patient unsuitable to&#xD;
             participate in this clinical trial.&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form.&#xD;
&#xD;
          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed&#xD;
             while taking pomalidomide.)&#xD;
&#xD;
          -  Subjects with any condition, including the presence of laboratory abnormalities, which&#xD;
             in the opinion of the Investigator places the subject at unacceptable risk if he/she&#xD;
             were to participate in the study or confounds the ability to interpret data from the&#xD;
             study.&#xD;
&#xD;
          -  Use of any other experimental drug or therapy within 14 days of baseline.&#xD;
&#xD;
          -  Subjects with a history of development of erythema nodosum, if characterized by a&#xD;
             desquamating rash, while taking thalidomide, lenalidomide, pomalidomide or similar&#xD;
             drugs.&#xD;
&#xD;
          -  Concurrent use of other anti-cancer agents or treatment.&#xD;
&#xD;
          -  Concomitant use of CYP3A4 inhibitors (See Appendix D)&#xD;
&#xD;
          -  Prior therapy with romidepsin, thalidomide or pomalidomide&#xD;
&#xD;
          -  Central nervous system or meningeal involvement&#xD;
&#xD;
          -  Patients taking drugs leading to significant QT prolongation&#xD;
&#xD;
          -  Known hypersensitivity to thalidomide or lenalidomide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Niesvizky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <results_first_submitted>October 30, 2017</results_first_submitted>
  <results_first_submitted_qc>January 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2018</results_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects were ineligible and therefore never started treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ALL Patients</title>
          <description>Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined (9mg/m2, 12 mg/m2, 15 mg/m2 or 18 mg/m2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALL Patients</title>
          <description>Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" lower_limit="58" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior lines of therapy</title>
          <units>Line of Prior Therapy</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta 2 Microglobulin</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.15" lower_limit="2" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lactate Dehydrogenase</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209.5" lower_limit="181" upper_limit="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Romidepsin in Combination With Pomalidomide and Dexamethasone</title>
        <description>Establish a maximum tolerated dose (MTD) of romidepsin in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (phase I)</description>
        <time_frame>During the duration of the study (from first to last dose of study drug, on average ten 28-day cycles)</time_frame>
        <population>MTD not established as study terminated while only 2 subjects enrolled. Only romidepsin dose tested was 9mg/mg2</population>
        <group_list>
          <group group_id="O1">
            <title>ALL Patients</title>
            <description>Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Romidepsin in Combination With Pomalidomide and Dexamethasone</title>
          <description>Establish a maximum tolerated dose (MTD) of romidepsin in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (phase I)</description>
          <population>MTD not established as study terminated while only 2 subjects enrolled. Only romidepsin dose tested was 9mg/mg2</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Study Regimen Combination</title>
        <description>The efficacy (as assessed by clinical response) of the combination of pomalidomide (CC-4047®) and romidepsin as therapy for patients with relapsed or refractory multiple myeloma (MM) (phase II portion) was evaluated using the IMWG Response Criteria for disease assessment. The best response was reported. (Criteria can be found at the following link, due to length and complexity of the response criteria: http://imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/)</description>
        <time_frame>From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALL Patients</title>
            <description>Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Study Regimen Combination</title>
          <description>The efficacy (as assessed by clinical response) of the combination of pomalidomide (CC-4047®) and romidepsin as therapy for patients with relapsed or refractory multiple myeloma (MM) (phase II portion) was evaluated using the IMWG Response Criteria for disease assessment. The best response was reported. (Criteria can be found at the following link, due to length and complexity of the response criteria: http://imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Progression of Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very Good Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression (Progression Free Survival)</title>
        <time_frame>From start of treatment, to date of disease progression (on average, ten 28-day cycles)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ALL Patients</title>
            <description>Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression (Progression Free Survival)</title>
          <units>cycles (defined as 28 days)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="1" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded from baseline until removal from study. Serious adverse events were recorded from baseline until 30 days after the last dose of study drug.</time_frame>
      <desc>Adverse events were recorded using the CTCAE version 4.0. Serious adverse events were recorded from baseline until 30 days after the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pomalidomide, Romidepsin, Dexamethasone</title>
          <description>Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone&#xD;
Romidepsin: Romidepsin intravenously on days 1 and 15 of a 28-day cycle&#xD;
pomalidomide: Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle&#xD;
Dexamethasone: Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea - intermittent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia - intermittent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stomach pain - epigastric area</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>jaw pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>pain - bilateral hips</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT elevation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>AST elevation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>nail infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Paresthesia around mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>tremors</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea with moderate exertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Hess</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>646-962-9440</phone>
      <email>jmh2004@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

